Cargando…
Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA
Epstein–Barr virus (EBV) is closely associated with nasopharyngeal carcinoma (NPC). Serum IgA antibodies against early antigen (EA‐IgA) and viral capsid antigen (VCA‐IgA) are the most commonly used to screen for NPC in endemic areas. However, the prognostic value of serum EA‐IgA and VCA‐IgA in patie...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543490/ https://www.ncbi.nlm.nih.gov/pubmed/28603915 http://dx.doi.org/10.1111/cas.13296 |
_version_ | 1783255158658957312 |
---|---|
author | Yao, Ji‐Jin Lin, Li Jin, Ya‐Nan Wang, Si‐Yang Zhang, Wang‐Jian Zhang, Fan Zhou, Guan‐Qun Cheng, Zhi‐Bin Qi, Zhen‐Yu Sun, Ying |
author_facet | Yao, Ji‐Jin Lin, Li Jin, Ya‐Nan Wang, Si‐Yang Zhang, Wang‐Jian Zhang, Fan Zhou, Guan‐Qun Cheng, Zhi‐Bin Qi, Zhen‐Yu Sun, Ying |
author_sort | Yao, Ji‐Jin |
collection | PubMed |
description | Epstein–Barr virus (EBV) is closely associated with nasopharyngeal carcinoma (NPC). Serum IgA antibodies against early antigen (EA‐IgA) and viral capsid antigen (VCA‐IgA) are the most commonly used to screen for NPC in endemic areas. However, the prognostic value of serum EA‐IgA and VCA‐IgA in patients with NPC is less clear. We hypothesize that serum EA‐IgA and VCA‐IgA levels have prognostic impact for survival outcomes in NPC patients with undetectable pretreatment EBV (pEBV) DNA. In this series, 334 patients with non‐metastatic NPC and undetectable pEBV DNA were included. Serum EA‐IgA and VCA‐IgA were determined by ELISA. After analysis, serum EA‐IgA and VCA‐IgA loads correlated positively with T, N, and overall stage (all P < 0.05). Serum EA‐IgA was not associated with survival outcome in univariable analyses. But patients with serum VCA‐IgA >1:120 had significantly inferior 5‐year progression‐free survival (80.4% vs 89.6%, P = 0.025), distant metastasis‐free survival (88.4% vs 94.8%, P = 0.050), and locoregional relapse‐free survival (88.4% vs 95.6%, P = 0.023; log–rank test). Multivariable analyses revealed that N stage was the only independent prognostic factor (all P < 0.05), but the VCA‐IgA became insignificant. Further analyses revealed that serum VCA‐IgA was not an independent prognostic factor in early N (N0–1) or advanced N (N2–3) stage NPC. In summary, although both EA‐IgA and VCA‐IgA correlate strongly with TNM stage, our analyses do not suggest that these antibodies are prognostic biomarkers in patients with NPC and undetectable pEBV DNA. |
format | Online Article Text |
id | pubmed-5543490 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55434902017-08-09 Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA Yao, Ji‐Jin Lin, Li Jin, Ya‐Nan Wang, Si‐Yang Zhang, Wang‐Jian Zhang, Fan Zhou, Guan‐Qun Cheng, Zhi‐Bin Qi, Zhen‐Yu Sun, Ying Cancer Sci Original Articles Epstein–Barr virus (EBV) is closely associated with nasopharyngeal carcinoma (NPC). Serum IgA antibodies against early antigen (EA‐IgA) and viral capsid antigen (VCA‐IgA) are the most commonly used to screen for NPC in endemic areas. However, the prognostic value of serum EA‐IgA and VCA‐IgA in patients with NPC is less clear. We hypothesize that serum EA‐IgA and VCA‐IgA levels have prognostic impact for survival outcomes in NPC patients with undetectable pretreatment EBV (pEBV) DNA. In this series, 334 patients with non‐metastatic NPC and undetectable pEBV DNA were included. Serum EA‐IgA and VCA‐IgA were determined by ELISA. After analysis, serum EA‐IgA and VCA‐IgA loads correlated positively with T, N, and overall stage (all P < 0.05). Serum EA‐IgA was not associated with survival outcome in univariable analyses. But patients with serum VCA‐IgA >1:120 had significantly inferior 5‐year progression‐free survival (80.4% vs 89.6%, P = 0.025), distant metastasis‐free survival (88.4% vs 94.8%, P = 0.050), and locoregional relapse‐free survival (88.4% vs 95.6%, P = 0.023; log–rank test). Multivariable analyses revealed that N stage was the only independent prognostic factor (all P < 0.05), but the VCA‐IgA became insignificant. Further analyses revealed that serum VCA‐IgA was not an independent prognostic factor in early N (N0–1) or advanced N (N2–3) stage NPC. In summary, although both EA‐IgA and VCA‐IgA correlate strongly with TNM stage, our analyses do not suggest that these antibodies are prognostic biomarkers in patients with NPC and undetectable pEBV DNA. John Wiley and Sons Inc. 2017-07-13 2017-08 /pmc/articles/PMC5543490/ /pubmed/28603915 http://dx.doi.org/10.1111/cas.13296 Text en © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Yao, Ji‐Jin Lin, Li Jin, Ya‐Nan Wang, Si‐Yang Zhang, Wang‐Jian Zhang, Fan Zhou, Guan‐Qun Cheng, Zhi‐Bin Qi, Zhen‐Yu Sun, Ying Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA |
title | Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA
|
title_full | Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA
|
title_fullStr | Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA
|
title_full_unstemmed | Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA
|
title_short | Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA
|
title_sort | prognostic value of serum epstein–barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment epstein–barr virus dna |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543490/ https://www.ncbi.nlm.nih.gov/pubmed/28603915 http://dx.doi.org/10.1111/cas.13296 |
work_keys_str_mv | AT yaojijin prognosticvalueofserumepsteinbarrvirusantibodiesinpatientswithnasopharyngealcarcinomaandundetectablepretreatmentepsteinbarrvirusdna AT linli prognosticvalueofserumepsteinbarrvirusantibodiesinpatientswithnasopharyngealcarcinomaandundetectablepretreatmentepsteinbarrvirusdna AT jinyanan prognosticvalueofserumepsteinbarrvirusantibodiesinpatientswithnasopharyngealcarcinomaandundetectablepretreatmentepsteinbarrvirusdna AT wangsiyang prognosticvalueofserumepsteinbarrvirusantibodiesinpatientswithnasopharyngealcarcinomaandundetectablepretreatmentepsteinbarrvirusdna AT zhangwangjian prognosticvalueofserumepsteinbarrvirusantibodiesinpatientswithnasopharyngealcarcinomaandundetectablepretreatmentepsteinbarrvirusdna AT zhangfan prognosticvalueofserumepsteinbarrvirusantibodiesinpatientswithnasopharyngealcarcinomaandundetectablepretreatmentepsteinbarrvirusdna AT zhouguanqun prognosticvalueofserumepsteinbarrvirusantibodiesinpatientswithnasopharyngealcarcinomaandundetectablepretreatmentepsteinbarrvirusdna AT chengzhibin prognosticvalueofserumepsteinbarrvirusantibodiesinpatientswithnasopharyngealcarcinomaandundetectablepretreatmentepsteinbarrvirusdna AT qizhenyu prognosticvalueofserumepsteinbarrvirusantibodiesinpatientswithnasopharyngealcarcinomaandundetectablepretreatmentepsteinbarrvirusdna AT sunying prognosticvalueofserumepsteinbarrvirusantibodiesinpatientswithnasopharyngealcarcinomaandundetectablepretreatmentepsteinbarrvirusdna |